US5141856A
(en)
*
|
1989-01-05 |
1992-08-25 |
Synergen, Inc. |
Expression of purified ciliary neurotrophic factor
|
US6472178B1
(en)
*
|
1998-02-27 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
|
US5349056A
(en)
*
|
1992-10-09 |
1994-09-20 |
Regeneron Pharmaceuticals |
Modified ciliary neurotrophic factors
|
TW248552B
(fr)
*
|
1993-06-01 |
1995-06-01 |
Onoda Yakuhin Kogyo Kk |
|
WO1995018150A1
(fr)
*
|
1993-12-29 |
1995-07-06 |
Sumitomo Pharmaceuticals Company, Limited |
Nouveau facteur neurotrophique ciliaire humain
|
AU7204996A
(en)
*
|
1995-10-02 |
1997-04-28 |
Cytotherapeutics, Inc. |
Method for treating amyotrophic lateral sclerosis
|
US5859311A
(en)
*
|
1995-11-27 |
1999-01-12 |
University Of Kentucky Research Foundation |
Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
|
IT1284867B1
(it)
|
1996-07-10 |
1998-05-22 |
Angeletti P Ist Richerche Bio |
Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
|
US6261545B1
(en)
|
1996-09-13 |
2001-07-17 |
Advanced Medicine Research Institute |
Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
|
IT1288388B1
(it)
*
|
1996-11-19 |
1998-09-22 |
Angeletti P Ist Richerche Bio |
Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
|
US20040120891A1
(en)
*
|
1998-12-21 |
2004-06-24 |
Craig Hill |
Compounds for intracellular delivery of therapeutic moieties to nerve cells
|
HUP0203057A3
(en)
*
|
1999-08-13 |
2005-07-28 |
Regeneron Pharma |
Modified ciliary neurotrophic factor, method of making and methods of use thereof
|
US7442370B2
(en)
*
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
AU2002253942A1
(en)
*
|
2001-02-12 |
2002-08-28 |
Michael Amling |
Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
|
US7276580B2
(en)
*
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
WO2003049673A2
(fr)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Procedes et compositions de regulation de formation d'os par modulation du tonus sympathique
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
WO2004037281A1
(fr)
*
|
2002-10-24 |
2004-05-06 |
The University Of British Columbia |
Procedes de neuroprotection
|
JP4571776B2
(ja)
*
|
2002-11-05 |
2010-10-27 |
Jx日鉱日石エネルギー株式会社 |
潤滑油組成物
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
WO2004094592A2
(fr)
|
2003-04-18 |
2004-11-04 |
Biogen Idec Ma Inc. |
Neublastine a conjugaison polymere glycosylee
|
GEP20084406B
(en)
|
2003-05-30 |
2008-06-25 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
US20050064555A1
(en)
*
|
2003-07-09 |
2005-03-24 |
Xencor, Inc. |
Ciliary neurotrophic factor variants
|
WO2005028438A1
(fr)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de piperidine
|
EP2305352A1
(fr)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
|
KR20110126732A
(ko)
*
|
2004-08-19 |
2011-11-23 |
바이오겐 아이덱 엠에이 인코포레이티드 |
뉴블라스틴 변형체
|
NZ553420A
(en)
|
2004-08-19 |
2010-02-26 |
Biogen Idec Inc |
Refolding transforming growth factor beta family proteins
|
EP1814590B2
(fr)
|
2004-11-01 |
2013-12-11 |
Amylin Pharmaceuticals, Inc. |
Traitement contre l'obesite ainsi que les maladies associees a l'obesite
|
US20060178301A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Mathias Jurs |
Albumin-fused ciliary neurotrophic factor
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
ES2574014T3
(es)
|
2005-05-30 |
2016-06-14 |
Msd K.K. |
Derivado de piperidina novedoso
|
EP1916239A4
(fr)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
Composé de pyridone
|
EP1921065B1
(fr)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé phénylpyridone
|
WO2007029847A1
(fr)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé de pyridone substitué aromatique bicylique
|
EP1940842B1
(fr)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
BRPI0707482A2
(pt)
*
|
2006-02-02 |
2011-05-03 |
Rinat Neuroscience Corp |
métodos para tratar perda indesejada de peso ou distúbios de alimentação por administração de um agonista de trkb, bem como uso de nt-4/5 e de um agonista de trkb
|
WO2007088479A1
(fr)
*
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corp. |
Procédés de traitement de l'obésité par administration d'un antagoniste trkb
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
EP1993590B1
(fr)
*
|
2006-03-01 |
2013-12-25 |
Biogen Idec MA Inc. |
Compositions et procedes d'administration de proteines de la famille des ligands gdnf
|
EP2698157B1
(fr)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
|
WO2008038692A1
(fr)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
dÉrivÉ de diarylcÉtimine
|
RU2009123491A
(ru)
*
|
2006-12-20 |
2010-12-27 |
Ринат Ньюросайенс Корпорейшн (Us) |
АГОНИСТЫ TrkB ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ НАРУШЕНИЙ
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
ES2476253T3
(es)
|
2007-05-01 |
2014-07-14 |
Biogen Idec Ma Inc. |
P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US20110135648A1
(en)
*
|
2007-08-08 |
2011-06-09 |
Biogen Idec Ma Inc. |
Anti-neublastin antibodies and uses thereof
|
US20100297081A1
(en)
*
|
2007-12-18 |
2010-11-25 |
Huang Yanshan |
Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
|
CA2714617A1
(fr)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Derive d'alkylaminopyridine
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
EP3239170B1
(fr)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
EP2301936A1
(fr)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé de spirodiamine-diarylcétoxime
|
EP3241839B1
(fr)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
|
EP2319841A1
(fr)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
|
CA2741125A1
(fr)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
|
WO2010051206A1
(fr)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
|
EP2379547A1
(fr)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2677869B1
(fr)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(fr)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
JP6769963B2
(ja)
|
2014-08-29 |
2020-10-14 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
EP3551176A4
(fr)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques antidiabétiques
|
EP3558298A4
(fr)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Composés de spirochromane antidiabétiques
|
CA3105879A1
(fr)
|
2018-07-18 |
2020-01-23 |
Manzanita Pharmaceuticals, Inc. |
Conjugues pour administrer un agent anticancereux a des cellules nerveuses, methodes d'utilisation et leurs procedes de fabrication
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|